p53 is a critical tumor suppressor that functions as a transcription factor. Mutations in the TP53 gene are observed in more than 50% of cancer cases worldwide. Several of these mutations lead to a less stable, aggregation-prone protein that accumulates in cancer cells. These mutations are associated with a gain of oncogenic function, which leads to cancer progression. p53 amyloid aggregation is a common feature in most of these mutants; thus, it can be used as a druggable target to reactivate or induce the degradation of p53 and promote a retraction in the aggressive pattern of mutant p53-containing cells. We show here a series of experiments for the screening and validation of new p53 antiamyloid compounds.
CITATION STYLE
Ferretti, G. D. da S., da Costa, D. C. F., L. Silva, J., & Pereira Rangel, L. (2019). Methods to screen compounds against mutant p53 misfolding and aggregation for cancer therapeutics. In Methods in Molecular Biology (Vol. 1873, pp. 265–277). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8820-4_17
Mendeley helps you to discover research relevant for your work.